Novartis' Partnership Ambitions
Novartis' rather public search for a co-promotion partner for tegaserod (Zelmac) has ended up garnering the Swiss firm a bigger partner than it might have expected-and a partner that badly needed a drug to sell--Bristol-Myers. But Novartis is doing more with this co-promotion than simply finding a co-promtoion partner and some quids--it's advertising its willingness to go outside of the company's walls for the firepower it needs and its belief in the necessity of more global partnerships--or perhaps one really big one.
You may also be interested in...
Contrasting first-quarter preannouncements from a DNA sequencing company and a molecular diagnostics company may, with other seasonal pressures, imply a comparatively weak first quarter for therapeutic drug companies.
The EU’s Medical Device Regulation applies in just over a month’s time and the IVD Regulation in just over a year. But the standards underpinning them are way behind. Will they get the green light at last
Gilead is closely evaluating the situation for remdesivir in India as the country tackles shortages of the drug, which has several local licensees, with instances of black marketing adding to the local woes. The US firm clearly will not want any momentum towards possible compulsory licensing as initiated by Hungary and Russia, even as Indian firms have cut prices of the antiviral.